350 related articles for article (PubMed ID: 32638417)
21. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
[TBL] [Abstract][Full Text] [Related]
22. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
23. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.
Zhang S; Ren X; Zhang B; Lan T; Liu B
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675679
[TBL] [Abstract][Full Text] [Related]
24. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.
van den Berg EH; Wolters AAB; Dullaart RPF; Moshage H; Zurakowski D; de Meijer VE; Blokzijl H
Liver Int; 2019 Jul; 39(7):1343-1354. PubMed ID: 30968536
[TBL] [Abstract][Full Text] [Related]
25. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
26. Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis.
Castillo-Leon E; Connelly MA; Konomi JV; Caltharp S; Cleeton R; Vos MB
Pediatr Obes; 2020 Sep; 15(9):e12648. PubMed ID: 32367624
[TBL] [Abstract][Full Text] [Related]
27. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
Athyros VG; Katsiki N; Doumas M
Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
[No Abstract] [Full Text] [Related]
28. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
29. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Corey KE; Wilson LA; Altinbas A; Yates KP; Kleiner DE; Chung RT; Krauss RM; Chalasani N;
Aliment Pharmacol Ther; 2019 May; 49(9):1205-1213. PubMed ID: 30854694
[TBL] [Abstract][Full Text] [Related]
30. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
31. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
Nseir W; Mograbi J; Ghali M
Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057
[TBL] [Abstract][Full Text] [Related]
32. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease.
Francque S; Vonghia L
Adv Ther; 2019 May; 36(5):1052-1074. PubMed ID: 30888594
[TBL] [Abstract][Full Text] [Related]
34. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.
An J; Sohn JH
Clin Mol Hepatol; 2023 Feb; 29(Suppl):S268-S275. PubMed ID: 36537018
[TBL] [Abstract][Full Text] [Related]
36. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?
Baran B; Akyüz F
World J Gastroenterol; 2014 Oct; 20(39):14219-29. PubMed ID: 25339808
[TBL] [Abstract][Full Text] [Related]
37. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
[TBL] [Abstract][Full Text] [Related]
38. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Blazina I; Selph S
Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
[TBL] [Abstract][Full Text] [Related]
40. Treatment options for managing atherogenic dyslipidemia and fatty liver disease.
Rizzo M; Montalto G; Al-Rasadi K
Expert Opin Pharmacother; 2014 Jun; 15(8):1065-8. PubMed ID: 24673432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
